CERAD test performance and cognitive impairment in Parkinson's disease.

Abstract

OBJECTIVES Many patients with Parkinson's disease (PD) develop mild cognitive impairment (PD-MCI) and dementia (PDD). The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) neurocognitive test battery was originally developed to identify early Alzheimer's disease, but it has become a widely used screening instrument also for other types of… (More)
DOI: 10.1111/ane.12138

Topics

  • Presentations referencing similar topics